Trial · NCT03989947
An Extension Study to Evaluate Safety and Efficacy of BMN 111 in Children With Achondroplasia
NCT03989947, Phase 2, Active not recruiting, BioMarin Pharmaceutical
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. An Extension Study to Evaluate Safety and Efficacy of BMN 111 in Children With Achondroplasia. Trials, record NCT03989947. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03989947
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- An Extension Study to Evaluate Safety and Efficacy of BMN 111 in Children With Achondroplasia
- NCT number
- NCT03989947
- Status
- Active not recruiting
- Phases
- Phase 2
- Enrollment
- 73 participants, actual
- Lead sponsor
- BioMarin Pharmaceutical
- Conditions
- Achondroplasia
- Interventions
- Active BMN 111: Subcutaneous injection of recommended dose of BMN 111 based on weight-band dosing once daily.
- First posted
- 2019-06-18
- Last updated
- 2026-03-13
Source ClinicalTrials.gov
Registered outcomes17
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Evaluate the incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] | "Through study completion, an average of 5 years" | Number of study participants with treatment-emergent adverse events or serious adverse events |
| Primary | Evaluate change in height/length z-score in children with ACH treated with BMN 111 | "Through study completion, an average of 5 years" | |
| Secondary | Evaluate the change from baseline of mean annualized growth velocity (AGV) | "Through study completion, an average of 5 years" | |
| Secondary | Characterize maximum concentration (Cmax) of BMN 111 in plasma | "Through study completion, an average of 5 years" | |
| Secondary | Characterize the area under the plasma concentration time-curve from time 0 to infinity (AUC0-∞) | "Through study completion, an average of 5 years" | |
| Secondary | Characterize the elimination half-life of BMN 111 (t½) | "Through study completion, an average of 5 years" | |
| Secondary | Characterize the apparent clearance of drug | "Through study completion, an average of 5 years" | |
| Secondary | Characterize the apparent volume of distribution based upon the terminal phase (Vz/F) | "Through study completion, an average of 5 years" | |
| Secondary | Characterize the amount of time BMN 111 is present at maximum concentration (Tmax) | "Through study completion, an average of 5 years" | |
| Secondary | Evaluate the change from baseline on body proportion ratios of the extremities | "Through study completion, an average of 5 years" |
1 to 10 of 17Source ClinicalTrials.gov
See all 17 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03989947
GET https://conductscience.org/api/trials/v1/NCT03989947/registered